Skip to main content

Table 3 Clinicopathological features of 12 skip N2 patients

From: Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer

Pt. no. Age/sex Side Location (lobe) Histology Tumor size (mm) Proportion of GGO (%) Distance to pleura (mm) SLX (U/mL) ly v pPL Site of skip N2
1 73/M Rt Upper Sq 15 19 4 36.2 + - 0 No. 2R, 4R LN
2 34/F Rt Upper Ad 16 68 13 27.4 + - 0 No.4R LN
3 70/F Rt Upper Ad 21 47 30 21.4 + + 0 No.2R, 4R LN
4 62/F Rt Upper Ad 14 24 28 13.1 + - 0 No. 4R LN
5 71/M Rt Lower Ad 30 9 0 40.2 - - 0 No. 7 LN
6 61/F Rt Lower Ad 24 27 0 32.8 + + 1 No. 7 LN
7 60 M Rt Lower Ad 24 23 0 29.0 + + 0 No.2R, 4R LN
8 62/F Lt Upper Ad 20 72 5 23.6 + + 1 No. 5 LN
9 81/M Lt Upper Sq 27 13 0 24.5 + - 2 No. 5 LN
10 63/M Lt Lower Ad 15 38 0 28.0 + - 0 No. 5 LN
11 60/M Lt Lower Ad 23 7 14 27.0 - + 0 No. 7 LN
12 57/F Lt Lower Ad 20 3 0 33.0 + - 0 No. 5 LN
  1. Pt. no., patient number; M,male; F, female; Rt, right; Lt, left; Ad, adenocarcinoma; Sq, squamous cell carcinoma; GGO, ground-glass opacity; distance to pleura, measured on computed-tomography; SLX, sialyl Lewis X; ly, lymph vessel invasion factor; v, venous invasion factor; pPL, pathological pleural invasion factor; No. 2R, upper paratracheal lymph node; No. 4R LN, lower paratracheal lymph node; No. 5 LN, subaortic lymph node; No. 7 LN, subcarinal lymph node.